From Hiv publication Mar 31, 2022: "All five
Post# of 155204
(Total Views: 357)
Posted On: 07/17/2025 9:05:52 AM
From Hiv publication Mar 31, 2022:
"All five human participants transitioned from daily combination ART to self-administered weekly subcutaneous (SC) injections of 350 mg or 700 mg Leronlimab and to date all participants have sustained virologic suppression for over seven years. In all participants, Leronlimab fully occupied CCR5 recep-tors on peripheral blood CD4+ T cells and monocytes."
"Low CD4+ T-cell counts in the blood is a hallmark of untreated HIV. Here, four of the five
participants had longitudinal CD4+ T-cell counts within the normal reference range (Fig 1F
and 1G), showing that long-term Leronlimab use does not negatively impact CD4+ T cell lev-
els. In fact, the dose change from 350 to 700 mg sequentially increased CD4+ T-cell counts in
all three participants from cohort 2 (p<0.0001). Notably, 01–038 was the only participant with
CD4+ T-cell counts below the normal range, likely attributable to the length of HIV infection
in this participant."
CD4+ T-cell hindsight, that's a couple good pieces of info ---
1. full RO on CD4+ T-cell too for 7 years.
(Outstanding)
2. No negative impact on those CF4+ T-cells.
(Outstanding)
Like Kat referenced days ago, they would of had to adress the blips. This study returned 7% Vs 2% average.
It's been a few yrs passed this trial....so feeling very positive
"All five human participants transitioned from daily combination ART to self-administered weekly subcutaneous (SC) injections of 350 mg or 700 mg Leronlimab and to date all participants have sustained virologic suppression for over seven years. In all participants, Leronlimab fully occupied CCR5 recep-tors on peripheral blood CD4+ T cells and monocytes."
"Low CD4+ T-cell counts in the blood is a hallmark of untreated HIV. Here, four of the five
participants had longitudinal CD4+ T-cell counts within the normal reference range (Fig 1F
and 1G), showing that long-term Leronlimab use does not negatively impact CD4+ T cell lev-
els. In fact, the dose change from 350 to 700 mg sequentially increased CD4+ T-cell counts in
all three participants from cohort 2 (p<0.0001). Notably, 01–038 was the only participant with
CD4+ T-cell counts below the normal range, likely attributable to the length of HIV infection
in this participant."
CD4+ T-cell hindsight, that's a couple good pieces of info ---
1. full RO on CD4+ T-cell too for 7 years.
(Outstanding)
2. No negative impact on those CF4+ T-cells.
(Outstanding)
Like Kat referenced days ago, they would of had to adress the blips. This study returned 7% Vs 2% average.
It's been a few yrs passed this trial....so feeling very positive
(4)
(0)